Subscribe to RSS
DOI: 10.1055/s-0035-1561945
Synthesis of 3-Pyrazolyl-1,2,4-Triazoles via One-Pot Multicomponent Reaction in Phosphoric Acid
Publication History
Received: 06 January 2016
Accepted after revision: 28 February 2016
Publication Date:
24 March 2016 (online)
Abstract
A high-yielding synthetic route towards pyrazolyl-[1,2,4]triazole derivatives has been developed via one-pot multicomponent reaction of polyfunctionalized triazoles, DMF–DMA, acetophenone, ethyl cyanoacetate, and/or 3-oxo-3-phenylpropanenitrile in ortho-phosphoric acid (85%). In the same manner, a new series of 2-triazolyl-tetrahydro-indazol-4-ones and pyrazolo[3,4-d]pyrimidines has been synthesized by reaction of triazoles, DMF–DMA and 1,3-cyclohexanediones and/or barbituric acid, respectively. The same products were prepared a classical manner via reaction of triazoles with the corresponding enaminones in ortho-phosphoric acid (85%).
Key words
pyrazolyl-[1,2,4]triazole - 2-triazolyl-tetrahydro-indazol-4-one - enaminone - multicomponent reaction - ortho-phosphoric acidSupporting Information
- Complete experimental procedures and characterization data of compounds 4 and 6–8 associated with this manuscript are found online at http://dx.doi.org/10.1055/s-0035-1561945.
- Supporting Information
-
References and Notes
- 1a Karakuş S, Çoruh U, Barlas-Durgun B, Ezequiel M, Suna Ö, Vázquez-López T, Sevim R. Marmara Pharm. J. 2010; 14: 84
- 1b Al-Soud YA, Al-Dweri MN, Al-Masoudi NA. Farmaco 2004; 59: 775
- 2a Farghaly A.-R, De Clercq E, El-Kashef H. ARKIVOC 2006; (x): 137
- 2b Abdel-Gawad H, Mohamed HA, Dawood KM, Badria FA. Chem. Pharm. Bull. 2010; 58: 15
- 3a Hussain S, Kaushik D, Sharma M. Eur. J. Sci. Res. 2010; 5: 257
- 3b Abdel-Megeed M, Hamdy MA, Gamal-Eldien SA, Mahmoud AE. Eur. J. Med. Chem. 2009; 44: 117
- 4 Li Z, Gu Z, Yin K, Zhang R, Deng Q, Xiang J. Eur. J. Med. Chem. 2009; 44: 4716
- 5a Mandal S, Dibyajyoti S, Vibhor KJ, Bindu J. Int. J. Appl. Bio. Pharm. Tech. 2010; 3: 1300
- 5b Al-Bay H, Quaddouri B, Guaadaoui A, Touzani R, Benchat N, Hamal A, Bellaoui M, El Kadiri S. Lett. Drug Des. Dis. 2010; 7: 41
- 5c Mares D, Romagnoli C, Andreotti E, Manfrini M, Beatr C. J. Agric. Food Chem. 2004; 52: 2003
- 6 Kane JM, Dudley MW, Sorensen SM, Francis PM. J. Med. Chem. 1988; 31: 1253
- 7 Khan I, Ali S, Hameed S, Rama NH, Hussain MT, Wadood A, Uddin R, Ul-Haq Z, Khan A, Ali S, Choudhary MI. Eur. J. Med. Chem. 2010; 45: 5200
- 8 SabManilarathnam Kiran GS, Sujith S, Shakir C, Selvin J. Asian J. Med. Sci. 2010; 2: 195
- 9 Akhtar T, Hameed S, Khan KM, Khan A, Choudhary MI. J. Enzyme Inhib. Med. Chem. 2010; 25: 572
- 10 Mhasalkar MY, Shah MH, Nikam ST. J. Med. Chem. 1971; 14: 260
- 11 Brucato A, Coppola A, Gianguzza S, Provenzano PM. Boll. Soc. Ital. Biol. Sper. 1978; 54: 1051
- 12 Povelitsa FD, Gural AG. Antibiotiki (Moscow) 1973; 18: 71 ; Chem. Abstr., 1973, 78, 93044
- 13 Shiroki M, Tahara T, Araki K. JP 75100096, 1975 ; Chem. Abstr., 1976, 84, 59588k
- 14 Coffen DL, Fryer RI. US, 3849434, 1974 ; Chem. Abstr., 1975, 82, 73044v
- 15 Wujec M, Pitucha M, Dobosz M, Kosikowska U, Malm A. Acta Pharm. 2004; 54: 251
- 16 Abdel-Rahman H, Farghal J. Chin. Chem. Soc. 2004; 51: 147
- 17a Shankaraiah N, Devaiah V, Reddy KL, Juvekar A, Sen S, Kurian N, Zingde S. Bioorg. Med. Chem. Lett. 2008; 18: 1468
- 17b Lee S, Seung BP. J. Org. Lett. 2009; 11: 5214
- 18 Sayed HH, Morsy EM. H, Flefel EM. Synth. Commun. 2010; 40: 1360
- 19a Riyadh SM, Abdelhamid IA, Al-Matar HM, Hilmy NM, Elnagdi MH. Heterocycles 2008; 75: 1849
- 19b Lue P, Greenhill JV. Adv. Heterocycl. Chem. 1997; 67: 207
- 19c Elassar AZ. A, El-Khair AA. Tetrahedron 2003; 59: 8463
- 19d Stanovnik B, Svete J. Chem. Rev. 2004; 104: 2433
- 19e Yermolayev SA, Gorobets NY, Lukinova EV, Shishkin OV, Shishkina SV, Desenko SM. Tetrahedron 2008; 64: 4649
- 19f Farghaly TA. J. Chem. Res. 2008; 152
- 19g Negri G, Kascheres C, Kascheres AJ. J. Heterocycl. Chem. 2004; 461
- 20 Dickinson RG, Jacobsen NW. Org. Prep. Proced. Int. 1974; 6: 156
- 21 Typical ProcedureMethod AA mixture of DMF–DMA (3, 0.01 mol) and acetophenone 2 (0.01 mol) was heated at 95–100 °C for 2 h, then 4-amino-5-hydrazino-4H-[1,2,4]triazol-3-thiol (1, 0.01 mol) in H3PO4 (60 mL) was added to the reaction mixture. The reaction mixture was then heated for a further 8 h at 95–100 °C. After completion of reaction (monitored with TLC), the reaction mixture was cooled to room temperature and poured onto ice-cold water. The precipitate that formed gradually was collected by filtration, washed several times with water, and dried.Method BEquimolar amounts (0.01 mol) of enaminone 5 and 4-amino-5-hydrazino-4H-[1,2,4]triazol-3-thiol 1 were heated in H3PO4 (60 mL) for 8 h at 95–100 °C. After completion of reaction (monitored with TLC), the reaction mixture was cooled to room temperature and poured into ice-cold water. The solid deposited was then collected by filtration, washed several times with water, and dried.
- 22a Marcelli T, Hammar P, Himo F. Chem. Eur. J. 2008; 14: 8562
- 22b Reuping M, Kuenkel A, Atodiresei I. Chem. Soc. Rev. 2011; 40: 4539
- 22c Bunrit A, Dahlstrand C, Olsson SK, Huang G, Biswas S, Himo F, Samec JS. M. Synlett 2016; 27: 173
- 23 4-Amino-5-(3-p-tolyl-pyrazol-1-yl)-4H-[1,2,4]-triazole-3-thiol (4c) Yellow solid, Methd A: 68% yield, Method B: 71% yield, mp 185–186 °C. IR (ATR): νmax = 3304, 3200, 3076, 3028, 2917, 1592 cm–1. 1H NMR (400 MHz, DMSO-d 6): δ = 14.00 (s, 1 H, SH), 8.44 (d, J = 2.6 Hz, 1 H, CHpyrazole), 7.83 (d, J = 7.9 Hz, 2 H, 2 CHphenyl), 7.30 (d, J = 7.9 Hz, 2 H, 2 CHphenyl), 7.11 (d, J = 2.6 Hz, 1 H, CHpyrazole), 5.81 (s, 2 H, NH2), 2.35 (s, 3 H, CH3). 13C NMR (100 MHz, DMSO-d 6): δ = 167.1, 154.0, 145.3, 138.7, 134.4, 129.8, 129.3, 126.2, 105.9, 21.3. Anal. Calcd for C12H12N6S (272): C, 52.93; H,4.44; N, 30.86. Found: C, 52.99; H, 4.39; N, 30.76.
- 24 Ethyl 3-Amino-1-(4-amino-5-mercapto-4H-[1,2,4]-triazol-3-yl)-1H-pyrazole-4-carboxylate (6a) Yellow solid, Method A: 61% yield, Method B: 61% yield, mp 119–120 °C. IR (ATR): νmax = 3431, 3318, 3259, 3176, 3112, 2983, 2959, 2904, 1683, 1631 cm–1. 1H NMR (400 MHz, DMSO-d 6): δ = 14.09 (s, 1 H, SH), 7.78 (s, 1 H, CHpyrazole), 6.85 (s, 2 H, NH2), 5.48 (s, 2 H, NH2), 4.22 (q, J = 7.0 Hz, 2 H, CH2), 1.28 (t, J = 7.0 Hz, 3 H, CH3). 13C NMR (100 MHz, DMSO-d 6): δ = 167.8, 163.3, 153.3, 143.4, 142.9, 93.5, 59.5, 14.9. Anal. Calcd for C8H11N7O2S (269): C, 35.68; H,4.12; N, 36.41. Found: C, 35.69; H, 4.10; N, 36.45.
- 25 2-(4-Amino-5-mercapto-4H-[1,2,4]triazol-3-yl)-6,6-dimethyl-2,5,6,7-tetrahydro-indazol-4-one (7b) Yellow solid, Method A: 78% yield, Method B: 84% yield, mp 249–251 °C. IR (ATR): νmax = 3300, 3200, 3166, 2957, 2930, 2870, 1674 cm–1. 1H NMR (400 MHz, DMSO-d 6): δ = 14.23 (s, 1 H, SH), 8.18 (s, 1 H, CHpyrazole), 5.72 (s, 2 H, NH2), 2.83 (s, 2 H, CH2), 2.40 (s, 2 H, CH2), 1.06 (s, 6 H, 2 CH3). 13C NMR (100 MHz, DMSO-d 6): δ = 192.2, 168.2, 153.9, 143.9, 139.8, 119.4, 52.0, 35.8, 34.5, 28.0. Anal. Calcd for C11H14N6OS (278): C, 47.47; H,5.07; N, 30.19. Found: C, 47.48; H, 5.00; N, 30.09.